Stabilizing MVA Virus Gene Inserts in Intergenic Regions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The stability of recombinant Modified Vaccinia Ankara (MVA) viruses expressing foreign genes, such as HIV genes, is compromised due to deletions and mutations during passage, leading to loss of gene expression and growth advantages for mutant viruses, which complicates large-scale production and clinical use.
Innovation Solution
Insertion of foreign genes between two essential vaccinia virus genes in the conserved central region of the MVA genome, using a plasmid transfer vector like pLW-73, and introduction of silent mutations in mutable regions to stabilize the gene inserts, preventing deletions and mutations that cause instability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If foreign genes are inserted into the MVA genome using conventional methods, then gene expression is achieved, but the recombinant viruses exhibit instability and undergo deletions during passage
Solution Approach 1:
The MVA genome is divided into conserved regions (essential genes) and variable regions (non-essential genes). The invention strategically selects insertion sites in intergenic regions between conserved genes, segmenting the genome to protect critical functions while allowing foreign gene integration in stable, non-essential zones.
Solution Approach 2:
The invention performs preliminary identification and selection of stable intergenic regions between conserved genes as insertion sites before introducing foreign genes. This preliminary action ensures that the insertion locations are pre-validated for stability, preventing subsequent deletions and mutations during virus passage.
2Productivity
If foreign genes are introduced into MVA, then vaccine expression is enabled, but deletions and mutations occur during passage leading to loss of gene expression
Solution Approach 1:
The invention applies local quality by selecting specific intergenic regions with distinct characteristics (between conserved genes) as insertion sites. These locations have unique properties that promote stability, contrasting with other genomic regions that are prone to mutations. The local genomic environment is optimized to maintain foreign gene expression.
Solution Approach 2:
The invention provides beforehand cushioning by choosing insertion sites buffered by conserved genes, which act as protective boundaries. These conserved genes prevent deletion of the foreign insert during viral replication, cushioning the insertion against harmful genetic changes and maintaining expression consistency.
3Ease of manufacture
If conventional insertion methods are used, then foreign gene integration is achieved, but mutant viruses gain growth advantages and outcompete wild-type
Solution Approach 1:
The invention extracts the problematic element (foreign gene) and places it in a protected environment (intergenic region between conserved genes). This extraction isolates the foreign gene from harmful genomic regions while maintaining its functionality, preventing it from becoming a growth disadvantage.
Solution Approach 2:
The invention changes the parameter of insertion site selection from random or conventional locations to specific intergenic regions between conserved genes. This parameter change fundamentally alters the stability outcome, transforming recombinant viruses from unstable to stable strains that maintain gene expression through multiple passages.
Data Source
AI summary
The present invention relates to new insertion sites useful for the integration of exogenous sequences into an intergenic region (IGR) of a vaccinia virus genome, where the IGR is located between or is flanked by two adjacent open reading frames (ORFs) of the vaccinia virus genome, and where the ORFs correspond to conserved genes, and to related plasmid vectors useful to insert exogenous DNA into the genome of a vaccinia virus, and further to recombinant vaccinia viruses comprising an exogenous sequence inserted into said new insertion site as a medicine or vaccine.